10-Q: Quoin Pharma Q1 2026: Increased R&D Spend, Cash Burn Continues

Quoin Pharmaceuticals reports a significant increase in R&D expenses for Q1 2026, alongside continued net losses and substantial doubt about its ability to continue as a going concern.

Summary

• Quoin Pharmaceuticals Ltd. (Quoin) filed its Form 10-Q for the quarterly period ended March 31, 2026.
• The company reported a net loss of $4,997,735 for the three months ended March 31, 2026, an increase from the $3,812,179 net loss in the same period of 2025.
• Total operating expenses rose to $5,131,210 from $3,957,177 in the prior year's quarter, driven primarily by a substantial increase in Research and Development (R&D) expenses.
• R&D expenses increased by 44.7% to $3,433,762 from $2,374,139, attributed to higher external expenditures on development programs, increased payroll, and stock-based compensation.
• General and administrative expenses also increased by 7.2% to $1,697,448 from $1,583,038.
• The company's cash and cash equivalents decreased to $3,124,523 from $3,818,096 at the end of 2025.
• Investments decreased to $10,918,778 from $14,927,165.
• The company has an accumulated deficit of approximately $76.0 million as of March 31, 2026.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date.
• The company is actively seeking additional funding through various means, including equity or debt offerings, and strategic partnerships.
• Regulatory updates include an application for Breakthrough Medicine Designation in Saudi Arabia for QRX003, Orphan Drug Designation application in Japan for QRX003, and Fast Track Designation granted by the FDA for QRX003 lotion.
• The FDA indicated that a single Phase 3 study may be sufficient for marketing approval of QRX003 in Netherton Syndrome, with openness to an alternate study design.
• The company plans to initiate investigator-led clinical studies for QRX009 in Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex.
• No products have been commercialized, and no revenue has been generated to date.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the increased net loss, rising operating expenses, and the explicit statement of substantial doubt regarding the company's ability to continue as a going concern, despite some positive regulatory developments.

Positives

• FDA granted Fast Track Designation to QRX003 lotion (4%) for Netherton Syndrome.
• FDA indicated openness to an alternate study design for a single Phase 3 study for QRX003 in Netherton Syndrome, potentially streamlining the approval process.
• Applications for Breakthrough Medicine Designation in Saudi Arabia and Orphan Drug Designation in Japan for QRX003 were filed, potentially leading to expedited review and market exclusivity.
• The company is expanding its development pipeline with plans to initiate investigator-led clinical studies for QRX009 in multiple rare diseases.
• The company has secured 9 commercial partnerships for QRX003 across 61 countries.
• Net cash provided by investing activities was $4,118,914, primarily from the sale of investments.
• Proceeds from the exercise of warrants provided $205,982 in financing activities.

Negatives

• The company reported a net loss of $4,997,735 for the quarter, an increase from the prior year's loss.
• Total operating expenses increased by $1,174,033, largely due to a significant rise in R&D spending.
• Cash and cash equivalents decreased by $693,573 during the quarter.
• Investments decreased by $3,908,387.
• The company has an accumulated deficit of $75,968,182.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern.
• The company has no revenue and expects to incur significant expenses for several more years before potential commercialization.
• The terms of the October 2025 private placement may make it difficult to procure additional financing.
• The company is dependent on third-party suppliers, including a single source for the active pharmaceutical ingredient (API) and contract manufacturer for drug product.

Risks

• The company must raise additional capital to fund its operations to continue as a going concern.
• There is substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date.
• The company has a limited operating history and a history of losses, with an accumulated deficit of $76.0 million.
• The company has no revenue and may be unable to be profitable.
• There are uncertainties regarding cash flows and the inability to meet working capital needs.
• The terms of the October 2025 private placement may make it difficult to procure additional financing.
• The company's ability to obtain regulatory approvals for its product candidates is uncertain.
• There is uncertainty regarding the generation of favorable pre-clinical and clinical trial results.
• The company faces potential inability to predict the timing of revenue from future product sales.
• Extensive regulatory requirements and future developmental and regulatory challenges remain even if approval is obtained.
• The company's manufacturing processes may not be validated, and its methodology may not be accepted by the scientific community.
• The ability to conduct clinical trials may be hindered by difficulties in enrolling patients or other reasons.
• The costs and demands of being a publicly traded company may harm the business.
• Potential adverse effects may result from failure to maintain effective internal controls.
• The company's ability to comply with Nasdaq's continued listing requirements is a risk.
• There is a risk of negative impact on the securities price and trading volume if analysts do not publish reports or change recommendations adversely.
• The market price for the company's ADSs is potentially volatile.
• There is potential dilution of shareholders' ownership due to future issuances of share capital.
• Holders of ADSs must act through the depositary to exercise their rights.
• There are potential limitations on ADS holders regarding the transfer of their ADSs.
• The company faces the risks of securities class action litigation.
• The company is dependent on several third-party suppliers, including a single source for API and contract manufacturer for drug product.

Future Outlook

The company expects its research and development expenses to remain significant over the next several years as it conducts late-stage clinical studies and prepares for regulatory approval of QRX003, begins clinical studies for QRX009, and potentially develops other product candidates. The company anticipates needing further funding through public or private offerings, debt financing, or strategic arrangements to complete development and fund operations until commercial profitability. The company does not expect to generate revenue from product sales for several years, subject to significant uncertainty.

Management Comments

• Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date of the filing of this Quarterly Report on Form 10-Q.
• The Company does not expect to generate revenue from product sales unless and until it successfully completes development and obtains marketing approval for one or more of its product candidates, which the Company expects will take a number of years and is subject to significant uncertainty.
• The Company will need to obtain further funding through public or private offerings of its capital stock, debt financing, pursuant to the exercise of warrants issued to investors in the Companys prior public and private offerings, collaboration, strategic and/or licensing arrangements or other sources in order to complete the research and development of the Companys product candidates and to fund the Companys other operating requirements until it achieves commercial profitability, if ever.
• If the Company is unable to obtain additional funding when it becomes necessary, the development of its product candidates will be impacted and the Company would likely be forced to delay, reduce, or terminate some or all of its development programs.

Industry Context

StockSavvy.ai notes that Quoin Pharmaceuticals operates in the highly competitive and capital-intensive biotechnology sector, focusing on rare and orphan diseases. The significant increase in R&D spending is typical for late-stage clinical companies, but the continued net losses and substantial doubt about going concern highlight the inherent risks and the critical need for future financing in this industry.

Comparison to Industry Standards

• Companies in the late-stage clinical development phase, particularly those focused on rare diseases, often experience substantial R&D expenses and net losses for extended periods, similar to Quoin Pharmaceuticals.
• The need for significant external financing (equity, debt, partnerships) is a common characteristic of the biotech industry, as drug development is lengthy and costly, with no guarantee of success. Quoin's reliance on future funding aligns with this industry standard.
• The pursuit of regulatory designations like Fast Track, Breakthrough Medicine, and Orphan Drug is a standard strategy employed by biopharmaceutical companies to expedite development and gain market advantages, as seen with Quoin's QRX003.
• The FDA's willingness to consider alternate study designs for pivotal trials, as indicated for QRX003, reflects a trend towards more efficient drug development pathways, especially for rare diseases, which is a positive development for companies in this space.

Legal Proceedings

• Management is unaware of any matters requiring accrual for related losses in the unaudited condensed consolidated financial statements.
• The company is currently not a party to any material legal or administrative proceedings, and is not aware of any pending or threatened material legal or administrative proceedings against it.

Related Party Transactions

• Two of the five 2020 Noteholders are related parties to the Company, with an aggregate estimated liability of $339,000 as of March 31, 2026 and December 31, 2025.
• Amounts due to officers (Dr. Myers and Ms. Carter) for accrued salaries, compensation, and expenses totaled $2,173,733 as of March 31, 2026, with $600,000 classified as short-term and $1,573,733 as long-term.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings, continued uncertainty regarding the company's going concern status, and potential loss of investment if operations cease.
• Employees: Increased R&D activities may lead to growth, but job security is tied to the company's ability to secure funding and achieve milestones.
• Creditors: The company's going concern status raises concerns about its ability to meet its financial obligations.
• Suppliers: Continued operations depend on securing funding, which impacts the company's ability to pay for services and materials.

Next Steps

• Complete late-stage clinical testing of QRX003 in Netherton Syndrome.
• File for marketing approval of QRX003 in the United States, Europe, Japan, and other territories.
• Prepare to commercialize QRX003 by establishing sales infrastructure and working with distribution partners.
• Continue development of QRX003 for Peeling Skin Syndrome.
• Commence clinical testing of topical rapamycin (QRX009) in selected indications.
• Pursue business development activities to expand the pipeline.
• Submit an IND to the FDA for QRX009 for an additional indication in Q3 2026.
• Schedule a meeting with QUT to discuss the future direction of the Scleroderma research program.
• Continue to seek sources of financing to fund operations and R&D programs.

Key Dates

Recommendation

Quoin Pharmaceuticals is a high-risk, speculative investment. While regulatory progress on QRX003 and pipeline expansion for QRX009 offer potential upside, the company's significant cash burn, lack of revenue, and explicit statement of substantial doubt about its ability to continue as a going concern are major red flags. Investors should monitor future financing activities and clinical trial results closely. A 'hold' recommendation reflects the balance between speculative potential and significant financial and operational risks.

Keywords

Quoin Pharmaceuticals, QNRX, Form 10-Q, Netherton Syndrome, QRX003, Rare Diseases, Orphan Diseases, Clinical Trials, FDA, Research and Development, Going Concern, Biotechnology, Pharmaceuticals